1. Home
  2. MTVA
  3. MTVA News

Latest METAVIA INC (MTVA) News on May 16, 2025

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
MTVA

PR Newswire

2 days ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
MTVA

PR Newswire

7 days ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
MTVA

PR Newswire

10 days ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
MTVA

PR Newswire

23 days ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
MTVA

PR Newswire

24 days ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…
MTVA

Zacks Small Cap Research

a month ago

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…

MTVA

MT Newswires

a month ago

MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
MTVA

PR Newswire

a month ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…
MTVA

Zacks Small Cap Research

2 months ago

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
MTVA

PR Newswire

2 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025
MTVA

Zacks Small Cap Research

4 months ago

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
MTVA

PR Newswire

4 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…
MTVA

Zacks Small Cap Research

5 months ago

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA

PR Newswire

5 months ago

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA

PR Newswire

5 months ago

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
MTVA

ACCESSWIRE

5 months ago

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
MTVA

GlobeNewswire

5 months ago

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
MTVA

Zacks Small Cap Research

5 months ago

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

MetaVia to Present at the Emerging Growth Conference in December
MTVA

PR Newswire

5 months ago

MetaVia to Present at the Emerging Growth Conference in December

Share on Social Networks: